ReachRxResearch
Home
Research
Sign Up
OpenFISH enables same-section spatial transcriptomics and MALDI-MSI integration
Back to Research Hub
  1. Home
  2. Research Hub
  3. OpenFISH enables same-section spatial tr…

OpenFISH enables same-section spatial transcriptomics and MALDI-MSI integration

Neuron·September 29
NeurosciencesPractice changingAlzheimer'S DiseaseNeurological DisordersProof-Of-Concept / Methods Development StudyMALDI Mass Spectrometry ImagingSpatial Multi-OmicsSpatial TranscriptomicsMixed

Summary

View source

What was studied

OpenFISH, an open-source, low-cost spatial transcriptomics platform, was evaluated for its ability to integrate with MALDI mass spectrometry imaging (MALDI-MSI) on the same tissue section, enabling co-mapping of cell-type identity (transcripts) and metabolic state (metabolites) at single-cell resolution in the central nervous system.

Key findings

OpenFISH successfully enabled same-section, cell-type-aware co-mapping of transcripts and metabolites, revealing cell-type-specific metabolic heterogeneity, hippocampal metabolic zonation, and—in 5xFAD Alzheimer's model tissue—phospholipid changes in microglia, metabolic shifts in excitatory neurons hidden in bulk analyses, and elevated lysophosphatidylethanolamine-related features in oligodendrocytes.

Study limitations

Findings from 5xFAD and Reeler mutant experiments are described as 'exploratory,' limiting causal or clinical conclusions; the platform has been demonstrated primarily in CNS tissue, so generalizability to other organs is unproven; single-cell metabolite spatial resolution depends on MALDI-MSI technical constraints.

Clinical implications

OpenFISH offers a customizable, low-cost framework for researchers to link cell identity to metabolic state within the same tissue section—currently a research tool rather than a clinical one, but it may accelerate mechanistic understanding of diseases like Alzheimer's where cell-type-specific metabolic changes are relevant.

Caveats

  • No human subjects or patient cohorts are included; all biological findings are from model organisms or in vitro preparations
  • The 5xFAD and Reeler mutant experiments are explicitly described as 'exploratory,' so metabolic findings in these disease models should be interpreted with caution and not yet generalized to human disease
  • This is a methods/platform paper demonstrated in animal (CNS) tissue; clinical or translational applicability has not been established

Related Questions

Explore related topics

What spatial transcriptomics platforms are compatible with mass spectrometry imaging for metabolomics?How do microglia phospholipid changes relate to Alzheimer's disease pathology in 5xFAD mouse models?What methods exist for integrating single-cell transcriptomics with metabolomics in brain tissue?

Publication Details

Year
2026
Journal
Neuron
Source
View article
Keep scrolling
More content below.
Up Next